Ovarian cancer stem cells: A new target for cancer therapy

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Zhan, Qinglei ^a   Wang, Chunmei ^a   Ngai, Saiming ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; BMI1 PROTEIN; CYTOPLASM PROTEIN; EPITHELIAL CELL ADHESION MOLECULE; GLUTATHIONE TRANSFERASE; MICRORNA; MICRORNA 199A; MICRORNA 214; MULTIDRUG RESISTANCE PROTEIN; P53 ASSOCIATED PARKIN LIKE CYTOPLASMIC PROTEIN; PROTEIN P53; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; BMI1 PROTEIN, HUMAN; GLUTATHIONE; TP53 PROTEIN, HUMAN;

APOPTOSIS; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL RENEWAL; CHEMOSENSITIVITY; DOWN REGULATION; GENE OVEREXPRESSION; HOMEOSTASIS; HUMAN; MULTIDRUG RESISTANCE; OVARY CANCER; OXIDATIVE STRESS; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECURRENT CANCER; REVIEW; SIGNAL TRANSDUCTION; TUMOR ESCAPE; CYTOLOGY; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; OVARY; OVARY TUMOR; PATHOLOGY; RECURRENT DISEASE;

BIOLOGICAL MARKERS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE; HUMANS; MICRORNAS; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; OVARY; POLYCOMB REPRESSIVE COMPLEX 1; RECURRENCE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84874644333     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/916819     Document Type: Review

References (129)

1. Howlader N., Noone A. M., Krapcho M., SEER Cancer Statistics Review 1975/2009 Bethesda, Md, USA National Cancer Institute. http://seer.cancer.gov/ csr/1975-2009-pops09/
2. Karst A. M., Drapkin R., Ovarian cancer pathogenesis: a model in evolution. Journal of Oncology 2010 2010 13 932371 10.1155/2010/932371
3. Chen V. W., Ruiz B., Killeen J. L., Coté T. R., Wu X. C., Correa C. N., Howe H. L., Pathology and classification of ovarian tumors. Cancer 2003 97 10 2631 2642 2-s2.0-0037629065 (Pubitemid 36539064)
4. Bast R. C. Jr., Hennessy B., Mills G. B., The biology of ovarian cancer: new opportunities for translation. Nature Reviews Cancer 2009 9 6 415 428 2-s2.0-67649440886
5. Kaku T., Ogawa S., Kawano Y., Ohishi Y., Kobayashi H., Hirakawa T., Nakano H., Histological classification of ovarian cancer. Medical Electron Microscopy 2003 36 1 9 17 2-s2.0-0037368503 10.1007/s007950300002 (Pubitemid 36504385)
6. Kurman R. J., Shih I. M., The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. American Journal of Surgical Pathology 2010 34 3 433 443 2-s2.0-77649219639 10.1097/PAS.0b013e3181cf3d79
7. Kurman R. J., Visvanathan K., Roden R., Wu T. C., Shih I. M., Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. American Journal of Obstetrics and Gynecology 2008 198 4 351 356 2-s2.0-41349101947 10.1016/j.ajog.2008.01.005 (Pubitemid 351451941)
8. Kim A., Ueda Y., Naka T., Therapeutic strategies in epithelial ovarian cancer. Journal of Experimental & Clinical Cancer Research 2012 31 1 14 22
9. Ferlay J., Parkin D. M., Steliarova-Foucher E., Estimates of cancer incidence and mortality in Europe in 2008. European Journal of Cancer 2010 46 4 765 781 2-s2.0-76049128595 10.1016/j.ejca.2009.12.014
10. Leitao M. M. Jr., Chi D. S., Surgical management of recurrent ovarian cancer. Seminars in Oncology 2009 36 2 106 111 2-s2.0-62949163716 10.1053/j.seminoncol.2008.12.002
11. Kim C. F., Dirks P. B., Cancer and stem cell biology: how tightly intertwined? Cell Stem Cell 2008 3 2 147 150 2-s2.0-48349098334 10.1016/j.stem.2008.07.012
12. Ahmed N., Abubaker K., Findlay J., Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance. Journal of Cellular Biochemistry 2013 114 1 21 34 10.1002/jcb.24317
13. Valent P., Bonnet D., De Maria R., Cancer stem cell definitions and terminology: the devil is in the details. Nature Reviews Cancer 2012 12 11 767 775 10.1038/nrc3368
14. Gupta P. B., Chaffer C. L., Weinberg R. A., Cancer stem cells: mirage or reality? Nature Medicine 2009 15 9 1010 1012 2-s2.0-69949129056 10.1038/nm0909-1010
15. Kitamura H., Okudela K., Yazawa T., Sato H., Shimoyamada H., Cancer stem cell: implications in cancer biology and therapy with special reference to lung cancer. Lung Cancer 2009 66 3 275 281 2-s2.0-70449522162 10.1016/j.lungcan.2009. 07.019
16. Steffensen K. D., Alvero A. B., Yang Y., Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. Journal of Oncology 2011 2011 12 620523 10.1155/2011/620523
17. Shibata M., Shen M. M., The roots of cancer: stem cells and the basis for tumor heterogeneity. BioEssays 2012 10.1002/bies.201200101
18. Wang X., Julio M. K. D., Economides K. D., Walker D., Yu H., Halili M. V., Hu Y. P., Price S. M., Abate-Shen C., Shen M. M., A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 2009 461 7263 495 500 2-s2.0-70349438989 10.1038/nature08361
19. Barker N., Clevers H., Tracking down the stem cells of the intestine: strategies to identify adult stem cells. Gastroenterology 2007 133 6 1755 1760 2-s2.0-36549004644 10.1053/j.gastro.2007.10.029 (Pubitemid 350180827)
20. Guddati A. K., Ovarian cancer stem cells: elusive targets for chemotherapy. Medical Oncology 2012 29 5 3400 3408 10.1007/s12032-012-0252-6
21. Bonnet D., Dick J. E., Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine 1997 3 7 730 737 2-s2.0-0030789242 10.1038/nm0797-730 (Pubitemid 27298715)
22. Zhang S., Balch C., Chan M. W., Lai H. C., Matei D., Schilder J. M., Yan P. S., Huang T. H. M., Nephew K. P., Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Research 2008 68 11 4311 4320 2-s2.0-49249091523 10.1158/0008-5472.CAN-08-0364
23. Bapat S. A., Mali A. M., Koppikar C. B., Kurrey N. K., Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Research 2005 65 8 3025 3029 2-s2.0-17144403478 (Pubitemid 40524578)
24. Lin K. K., Goodell M. A., Purification of hematopoietic stem cells using the side population. Methods in Enzymology 2006 420 255 264 2-s2.0-33845222483 10.1016/S0076-6879(06)20011-9 (Pubitemid 44855867)
25. Szotek P. P., Pieretti-Vanmarcke R., Masiakos P. T., Dinulescu D. M., Connolly D., Foster R., Dombkowski D., Preffer F., MacLaughlin D. T., Donahoe P. K., Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proceedings of the National Academy of Sciences of the United States of America 2006 103 30 11154 11159 2-s2.0-33746625091 10.1073/pnas.0603672103 (Pubitemid 44156488)
26. Gao Q., Geng L., Kvalheim G., Gaudernack G., Suo Z., Identification of cancer stem-like side population cells in ovarian cancer cell line OVCAR-3. Ultrastructural Pathology 2009 33 4 175 181 2-s2.0-70149124370 10.3109/01913120903086072
27. Zeimet A. G., Reimer D., Sopper S., Ovarian cancer stem cells. Neoplasma 2012 59 6 747 755 10.4149/neo-2012-094
28. Ahmed N., Abubaker K., Findlay J., Quinn M., Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Current Cancer Drug Targets 2010 10 3 268 278 2-s2.0-77952855239 10.2174/156800910791190175
29. Hu L., McArthur C., Jaffe R. B., Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. British Journal of Cancer 2010 102 8 1276 1283 2-s2.0-77950862035 10.1038/sj.bjc.6605626
30. Anderson M. E., Glutathione: an overview of biosynthesis and modulation. Chemico-Biological Interactions 1998 111-112 1 14 10.1016/S0009-2797(97)00146-4 (Pubitemid 28271929)
31. Kamazawa S., Kigawa J., Kanamori Y., Itamochi H., Sato S., Iba T., Terakawa N., Multidrug resistance gene-1 is a useful predictor of paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecologic Oncology 2002 86 2 171 176 2-s2.0-0036351238 10.1006/gyno.2002.6738 (Pubitemid 34953500)
32. Backos D. S., Franklin C. C., Reigan P., The role of glutathione in brain tumor drug resistance. Biochem Pharmacol 2012 83 8 1005 1012 10.1016/j.bcp.2011.11.016
33. Jedlitschky G., Leier I., Buchholz U., Center M., Keppler D., ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Research 1994 54 18 4833 4836 2-s2.0-0028001416 (Pubitemid 24289409)
34. Colvin O. M., Friedman H. S., Gamcsik M. P., Fenselau C., Hilton J., Role of glutathione in cellular resistance to alkylating agents. Advances in Enzyme Regulation 1993 33 19 26 2-s2.0-0027367672 10.1016/0065-2571(93)90006-Y (Pubitemid 223051907)
35. Lessard J., Sauvageau G., Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003 423 6937 255 260 2-s2.0-0037673984 10.1038/nature01572 (Pubitemid 40852690)
36. Liu J., Cao L., Chen J., Song S., Lee I. H., Quijano C., Liu H., Keyvanfar K., Chen H., Cao L. Y., Ahn B. H., Kumar N. G., Rovira I. I., Xu X. L., Van Lohuizen M., Motoyama N., Deng C. X., Finkel T., Bmi1 regulates mitochondrial function and the DNA damage response pathway. Nature 2009 459 7245 387 392 2-s2.0-67349156082 10.1038/nature08040
37. Li J., Gong L. Y., Song L. B., Jiang L. L., Liu L. P., Wu J., Yuan J., Cai J. C., He M., Wang L., Zeng M., Cheng S. Y., Li M., Oncoprotein Bmi-1 renders apoptotic resistance to glioma cells through activation of the IKK-nuclear factor- B pathway. American Journal of Pathology 2010 176 2 699 709 2-s2.0-76149111625 10.2353/ajpath.2010.090502
38. Guo B. H., Feng Y., Zhang R., Xu L. H., Li M. Z., Kung H. F., Song L. B., Zeng M. S., Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer. Molecular Cancer 2011 10, article 10 2-s2.0-79251589918 10.1186/1476-4598-10-10
39. Wang E., Bhattacharyya S., Szabolcs A., Rodriguez-Aguayo C., Jennings N. B., Lopez-Berestein G., Mukherjee P., Sood A. K., Bhattacharya R., Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. PLoS ONE 2011 6 3 2-s2.0-79952824058 10.1371/journal.pone.0017918 e17918
40. Wallace-Brodeur R. R., Lowe S. W., Clinical implications of p53 mutations. Cellular and Molecular Life Sciences 1999 55 1 64 75 2-s2.0-0033054908 10.1007/s000180050270 (Pubitemid 29077855)
41. Fraser M., Bai T., Tsang B. K., Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. International Journal of Cancer 2008 122 3 534 546 2-s2.0-37349060695 10.1002/ijc.23086 (Pubitemid 350308944)
42. Nikolaev A. Y., Li M., Puskas N., Qin J., Gu W., Parc: a cytoplasmic anchor for p53. Cell 2003 112 1 29 40 2-s2.0-0037428078 10.1016/S0092-8674(02) 01255-2 (Pubitemid 36106416)
43. Woo M. G., Xue K., Liu J., Calpain-mediated processing of p53-associated parkin-like cytoplasmic protein (PARC) affects chemosensitivity of human ovarian cancer cells by promoting p53 subcellular trafficking. The Journal of Biological Chemistry 2012 287 6 3963 3975 10.1074/jbc.M111.314765
44. Herr I., Debatin K. M., Cellular stress response and apoptosis in cancer therapy. Blood 2001 98 9 2603 2614 2-s2.0-0035525733 10.1182/blood.V98.9.2603
45. Gillet J. P., Gottesman M. M., Mechanisms of multidrug resistance in cancer. Methods in Molecular Biology 2010 596 1064-3745 47 76 2-s2.0-73949135792
46. Ernst R., Kueppers P., Stindt J., Kuchler K., Schmitt L., Multidrug efflux pumps: substrate selection in ATP-binding cassette multidrug efflux pumps-first come, first served? FEBS Journal 2010 277 3 540 549 2-s2.0-75149114141 10.1111/j.1742-4658.2009.07485.x
47. Juliano R. L., Ling V., A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochimica et Biophysica Acta 1976 445 1 152 162 2-s2.0-0017142032
48. Surowiak P., Materna V., Kaplenko I., Spaczynski M., Dolinska-Krajewska B., Gebarowska E., Dietel M., Zabel M., Lage H., ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. Clinical Cancer Research 2006 12 23 7149 7158 2-s2.0-33845724571 10.1158/1078-0432.CCR-06-0564 (Pubitemid 44974516)
49. Zhou S., Schuetz J. D., Bunting K. D., Colapietro A. M., Sampath J., Morris J. J., Lagutina I., Grosveld G. C., Osawa M., Nakauchi H., Sorrentino B. P., The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nature Medicine 2001 7 9 1028 1034 2-s2.0-0034795256 10.1038/nm0901-1028 (Pubitemid 32937383)
50. Alvi A. J., Clayton H., Joshi C., Enver T., Ashworth A., Vivanco M. M., Dale T. C., Smalley M. J., Functional and molecular characterisation of mammary side population cells. Breast Cancer Research 2003 5 1 R1 R8 2-s2.0-1642486729
51. Hosonuma S., Kobayashi Y., Kojo S., Clinical significance of side population in ovarian cancer cells. Human Cell 2011 24 1 9 12
52. van Herwaarden A. E., Wagenaar E., Karnekamp B., Merino G., Jonker J. W., Schinkel A. H., Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. Carcinogenesis 2006 27 1 123 130 2-s2.0-29744441900 10.1093/carcin/bgi176 (Pubitemid 43025252)
53. Aguilar-Gallardo C., Rutledge E. C., Martinez-Arroyo A. M., Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches. Stem Cell Reviews 2012 8 3 994 1010
54. Wender P. A., Galliher W. C., Bhat N. M., Taxol-oligoarginine conjugates overcome drug resistance in-vitro in human ovarian carcinoma. Gynecologic Oncology 2012 126 1 118 123
55. Arai F., Hirao A., Ohmura M., Sato H., Matsuoka S., Takubo K., Ito K., Koh G. Y., Suda T., Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 2004 118 2 149 161 2-s2.0-3242669145 10.1016/j.cell.2004.07.004 (Pubitemid 38962572)
56. Liu Y., Elf S. E., Miyata Y., Sashida G., Liu Y., Huang G., Di Giandomenico S., Lee J. M., Deblasio A., Menendez S., Antipin J., Reva B., Koff A., Nimer S. D., p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell 2009 4 1 37 48 2-s2.0-58049216794 10.1016/j.stem.2008.11.006
57. Asai T., Liu S Y., Di Giandomenico S., Necdin, a p53 target gene, regulates the quiescence and response to genotoxic stress of hematopoietic stem/progenitor cells. Blood 2012 120 8 1601 1612 10.1182/blood-2011-11-393983
58. Hock H., Hamblen M. J., Rooke H. M., Schindler J. W., Saleque S., Fujiwara Y., Orkin S. H., Gfi-1 restricts proliferation and preserves functional integrity of haematopoietic stem cells. Nature 2004 431 7011 1002 1007 2-s2.0-7244231429 10.1038/nature02994 (Pubitemid 39434423)
59. Du J., Chen Y., Li Q., HIF-1alpha deletion partially rescues defects of hematopoietic stem cell quiescence caused by Cited2 deficiency. Blood 2012 119 12 2789 2798
60. Hua S., Xiaotao X., Renhua G., Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells. Biomedicine & Pharmacotherapy 2012 66 2 89 97
61. Scott A. M., Wolchok J. D., Old L. J., Antibody therapy of cancer. Nature Reviews Cancer 2012 12 4 278 287
62. Burgos-Ojeda D., Rueda B. R., Buckanovich R. J., Ovarian cancer stem cell markers: prognostic and therapeutic implications. Cancer Letters 2012 322 1 1 7 10.1016/j.canlet.2012.02.002
63. Ferrandina G., Bonanno G., Pierelli L., Perillo A., Procoli A., Mariotti A., Corallo M., Martinelli E., Rutella S., Paglia A., Zannoni G., Mancuso S., Scambia G., Expression of CD133-1 and CD133-2 in ovarian cancer. International Journal of Gynecological Cancer 2008 18 3 506 514 2-s2.0-43449110421 10.1111/j.1525-1438.2007.01056.x (Pubitemid 351668323)
64. Long H., Xie R., Xiang T., Autocrine CCL5 signaling promotes invasion and migration of CD133 (+) ovarian cancer stem-like cells via NF-kappaB-mediated MMP-9 upregulation. Stem Cells 2012 30 10 2309 2319
65. Baba T., Convery P. A., Matsumura N., Whitaker R. S., Kondoh E., Perry T., Huang Z., Bentley R. C., Mori S., Fujii S., Marks J. R., Berchuck A., Murphy S. K., Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009 28 2 209 218 2-s2.0-58249095085 10.1038/onc.2008.374
66. Smith L. M., Nesterova A., Ryan M. C., CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. British Journal of Cancer 2008 99 1 100 109 10.1038/sj.bjc.6604437 (Pubitemid 351920235)
67. Naor D., Sionov R. V., Ish-Shalom D., CD44: structure, function, and association with the malignant process. Advances in Cancer Research 1997 71 241 319 2-s2.0-0030966842 (Pubitemid 27197761)
68. Marhaba R., Klingbeil P., Nuebel T., Nazarenko I., Buechler M. W., Zoeller M., CD44 and EpCAM: cancer-initiating cell markers. Current Molecular Medicine 2008 8 8 784 804 2-s2.0-59249094144 10.2174/156652408786733667
69. Meng E., Long B., Sullivan P., CD44+/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival. Clinical & Experimental Metastasisdoi 2012 29 8 939 948 10.1007/s10585-012-9482-4
70. Heider K. H., Kuthan H., Stehle G., Munzert G., CD44v6: a target for antibody-based cancer therapy. Cancer Immunology, Immunotherapy 2004 53 7 567 579 2-s2.0-2342537511 10.1007/s00262-003-0494-4 (Pubitemid 38858330)
71. Ghosh S. C., Alpay S. N., Klostergaard J., CD44: a validated target for improved delivery of cancer therapeutics. Expert Opinion on Therapeutic Targets 2012 16 7 635 650 10.1517/14728222.2012.687374
72. Börjesson P. K. E., Postema E. J., Roos J. C., Colnot D. R., Marres H. A. M., Van Schie M. H., Stehle G., De Bree R., Snow G. B., Oyen W. J. G., Van Dongen G. A. M. S., Phase I therapy study with 186Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with head and neck squamous cell carcinoma. Clinical Cancer Research 2003 9 10 3961S 3972S 2-s2.0-10844290511 (Pubitemid 37169203)
73. Casagrande F., Cocco E., Bellone S., Eradication of chemotherapy- resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer 2011 117 24 5519 5528 10.1002/cncr.26215
74. Orian-Rousseau V., CD44, a therapeutic target for metastasising tumours. European Journal of Cancer 2010 46 7 1271 1277 2-s2.0-77950561915 10.1016/j.ejca.2010.02.024
75. Kristiansen G., Sammar M., Altevogt P., Tumour biological aspects of CD24, a mucin-like adhesion molecule. Journal of Molecular Histology 2004 35 3 255 262 2-s2.0-13544263786 10.1023/B:HIJO.0000032357.16261.c5 (Pubitemid 40585311)
76. Gao M. Q., Choi Y. P., Kang S., Youn J. H., Cho N. H., CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 2010 29 18 2672 2680 2-s2.0-77952240931 10.1038/onc.2010.35
77. Surowiak P., Materna V., Kaplenko I., Spaczyński M., Dietel M., Kristiansen G., Lage H., Zabel M., Unfavorable prognostic value of CD24 expression in sections from primary and relapsed ovarian cancer tissue. International Journal of Gynecological Cancer 2006 16 2 515 521 2-s2.0-33646061670 10.1111/j.1525-1438.2006.00555.x (Pubitemid 44410957)
78. Choi Y. L., Kim S. H., Shin Y. K., Hong Y. C., Lee S. J., Kang S. Y., Ahn G., Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors. Gynecologic Oncology 2005 97 2 379 386 2-s2.0-18144377958 10.1016/j.ygyno.2005. 01.018 (Pubitemid 40614878)
79. Bretz N. P., Salnikov A. V., Perne C., CD24 controls Src/STAT3 activity in human tumors. Cellular and Molecular Life Sciences 2012 69 22 3863 3879 10.1007/s00018-012-1055-9
80. Su D., Deng H., Zhao X., Zhang X., Chen L., Chen X., Li Z., Bai Y., Wang Y., Zhong Q., Yi T., Qian Z., Wei Y., Targeting CD24 for treatment of ovarian cancer by short hairpin RNA. Cytotherapy 2009 11 5 642 652 2-s2.0-70849134276 10.1080/14653240902878308
81. Miettinen M., Lasota J., KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Applied Immunohistochemistry and Molecular Morphology 2005 13 3 205 220 2-s2.0-23944452835 10.1097/01.pai.0000173054.83414.22 (Pubitemid 41209013)
82. Bapat S. A., Mali A. M., Koppikar C. B., Kurrey N. K., Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Research 2005 65 8 3025 3029 2-s2.0-17144403478 (Pubitemid 40524578)
83. Luo L., Zeng J., Liang B., Zhao Z., Sun L., Cao D., Yang J., Shen K., Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome. Experimental and Molecular Pathology 2011 91 2 596 602 2-s2.0-79961119901 10.1016/j.yexmp.2011.06.005
84. Raspollini M. R., Amunni G., Villanucci A., Baroni G., Taddei A., Taddei G. L., c-KIT expression and correlation with chemotherapy resistance in ovarian carcinoma: an immunocytochemical study. Annals of Oncology 2004 15 4 594 597 2-s2.0-2342418119 10.1093/annonc/mdh139 (Pubitemid 38559594)
85. Chau W. K., Ip C. K., Mak A. S., c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/beta-catenin-ATP-binding cassette G2 signaling. Oncogene 2012 10.1038/onc.2012.290
86. Schilder R. J., Sill M. W., Lee R. B., Shaw T. J., Senterman M. K., Klein-Szanto A. J., Miner Z., Vanderhyden B. C., Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. Journal of Clinical Oncology 2008 26 20 3418 3425 2-s2.0-49149108140 10.1200/JCO.2007.14. 3420
87. Patel B. B., He Y. A., Li X. M., Frolov A., Vanderveer L., Slater C., Schilder R. J., Von Mehren M., Godwin A. K., Yeung A. T., Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysis. Cancer Genomics and Proteomics 2008 5 3-4 137 150 2-s2.0-46849094734 (Pubitemid 351957305)
88. Imrich S., Hachmeister M., Gires O., EpCAM and its potential role in tumor-initiating cells. Cell Adhesion & Migration 2012 6 1 30 38
89. Pauli C., Münz M., Kieu C., Mack B., Breinl P., Wollenberg B., Lang S., Zeidler R., Gires O., Tumor-specific glycosylation of the carcinoma-associated epithelial cell adhesion molecule EpCAM in head and neck carcinomas. Cancer Letters 2003 193 1 25 32 2-s2.0-0345830844 10.1016/S0304-3835(03)00003-X (Pubitemid 36416612)
90. Gosens M. J. E. M., Van Kempen L. C. L., Van De Velde C. J. H., Van Krieken J. H. J. M., Nagtegaal I. D., Loss of membranous Ep-CAM in budding colorectal carcinoma cells. Modern Pathology 2007 20 2 221 232 2-s2.0-33947283773 10.1038/modpathol.3800733 (Pubitemid 46422177)
91. Baeuerle P. A., Gires O., EpCAM (CD326) finding its role in cancer. British Journal of Cancer 2007 96 3 417 423 2-s2.0-33846804010 10.1038/sj.bjc.6603494 (Pubitemid 46215211)
92. Thiery J. P., Acloque H., Huang R. Y. J., Nieto M. A., Epithelial-mesenchymal transitions in development and disease. Cell 2009 139 5 871 890 2-s2.0-70450198396 10.1016/j.cell.2009.11.007
93. Sebastian M., Kuemmel A., Schmidt M., Schmittel A., Catumaxomab: a bispecific trifunctional antibody. Drugs of Today 2009 45 8 589 597 2-s2.0-76149112551 1396673/dot.2009.45.8.1401103
94. Seimetz D., Lindhofer H., Bokemeyer C., Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy. Cancer Treatment Reviews 2010 36 6 458 467 2-s2.0-77956344338 10.1016/j.ctrv.2010.03.001
95. Marchitti S. A., Brocker C., Stagos D., Vasiliou V., Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opinion on Drug Metabolism and Toxicology 2008 4 6 697 720 2-s2.0-48949117163 10.1517/17425255.4.6.697 (Pubitemid 352003194)
96. Landen C. N. Jr., Goodman B., Katre A. A., Steg A. D., Nick A. M., Stone R. L., Miller L. D., Mejia P. V., Jennings N. B., Gershenson D. M., Bast R. C., Coleman R. L., Lopez-Berestein G., Sood A. K., Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Molecular Cancer Therapeutics 2010 9 12 3186 3199 2-s2.0-78650455641 10.1158/1535-7163.MCT-10-0563
97. Saw Y. T., Yang J., Ng S. K., Characterization of aldehyde dehydrogenase isozymes in ovarian cancer tissues and sphere cultures. BMC Cancer 2012 12, article 329 10.1186/1471-2407-12-329
98. Silva I. A., Bai S., McLean K., Yang K., Griffith K., Thomas D., Ginestier C., Johnston C., Kueck A., Reynolds R. K., Wicha M. S., Buckanovich R. J., Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Research 2011 71 11 3991 4001 2-s2.0-79957917044 10.1158/0008-5472.CAN-10-3175
99. Liu P., Brown S., Goktug T., Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells. British Journal of Cancer 2010 107 9 1488 1497
100. Khanna M., Chen C. H., Kimble-Hill A., Discovery of a novel class of covalent inhibitor for aldehyde dehydrogenases. The Journal of Biological Chemistry 2011 286 50 43486 43494
101. Peng S., Maihle N. J., Huang Y., Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer. Oncogene 2010 29 14 2153 2159 2-s2.0-77950794030 10.1038/onc.2009.500
102. Masiakos P. T., MacLaughlin D. T., Maheswaran S., Teixeira J., Fuller A. F., Shah P. C., Kehas D. J., Kenneally M. K., Dombkowski D. M., Ha T. U., Preffer F. I., Donahoe P. K., Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Clinical Cancer Research 1999 5 11 3488 3499 2-s2.0-0032753468
103. Wei X., Dombkowski D., Meirelles K., Pieretti-Vanmarcke R., Szotek P. P., Chang H. L., Preffer F. I., Mueller P. R., Teixeira J., MacLaughlin D. T., Donaho P. K., Müllerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics. Proceedings of the National Academy of Sciences of the United States of America 2010 107 44 18874 18879 2-s2.0-78649908639 10.1073/pnas.1012667107
104. Sell S., Stem cell origin of cancer and differentiation therapy. Critical Reviews in Oncology/Hematology 2004 51 1 1 28 2-s2.0-2942691389 10.1016/j.critrevonc.2004.04.007 (Pubitemid 38781748)
105. Yin G., Alvero A. B., Craveiro V., Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential. Oncogene 2013 32 1 39 49 10.1038/onc.2012.33
106. Jain A. K., Allton K., Iacovino M., p53 regulates cell cycle and microRNAs to promote differentiation of human embryonic stem cells. PLoS Biology 2012 10 2 e1001268
107. Yu Z., Li Y., Fan H., miRNAs regulate stem cell self-renewal and differentiation. Frontiers in Genetics 2012 3 191 195
108. Gudas L. J., Wagner J. A., Retinoids regulate stem cell differentiation. Journal of Cellular Physiology 2011 226 2 322 330 2-s2.0-78649646015 10.1002/jcp.22417
109. Lim Y. C., Kang H. J., Kim Y. S., All-trans-retinoic acid inhibits growth of head and neck cancer stem cells by suppression of Wnt/beta-catenin pathway. European Journal of Cancer 2012 48 17 3310 3318 10.1016/j.ejca.2012.04.013
110. Soignet S. L., Benedetti F., Fleischauer A., Parker B. A., Truglia J. A., Ra Crisp M., Warrell R. P., Clinical study of 9-cis retinoic acid (LGD1057) in acute promyelocytic leukemia. Leukemia 1998 12 10 1518 1521 2-s2.0-0031656210 (Pubitemid 28470433)
111. Whitworth J. M., Londono-Joshi A. I., Sellers J. C., The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells. Gynecologic Oncology 2012 125 1 226 230
112. Ruiz-Vela A., Aguilar-Gallardo C., Martinez-Arroyo A. M., Specific unsaturated fatty acids enforce the transdifferentiation of human cancer cells toward adipocyte-like cells. Stem Cell Reviews 2011 7 4 898 909 10.1007/s12015-011-9253-7
113. Ruiz-Vela A., Aguilar-Gallardo C., Simón C., Building a framework for embryonic microenvironments and cancer stem cells. Stem Cell Reviews and Reports 2010 5 4 319 327 2-s2.0-74649085850 10.1007/s12015-009-9096-7
114. Li H. J., Reinhardt F., Herschman H. R., Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discovery 2012 2 9 840 855 10.1158/2159-8290.CD-12-0101
115. Lis R., Touboul C., Raynaud C. M., Mesenchymal cell interaction with ovarian cancer cells triggers pro-metastatic properties. PLoS One 2012 7 5 10.1371/journal.pone.0038340 e38340
116. Katz E., Skorecki K., Tzukerman M., Niche-dependent tumorigenic capacity of malignant ovarian ascites-derived cancer ceil subpopulations. Clinical Cancer Research 2009 15 1 70 80 2-s2.0-58849134940 10.1158/1078-0432.CCR-08-1233
117. Liang D., Ma Y., Liu J., The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells. BMC Cancer 2012 12 201 211 10.1186/1471-2407-12-201
118. LaBarge M. A., The difficulty of targeting cancer stem cell niches. Clinical Cancer Research 2010 16 12 3121 3129 2-s2.0-77953722864 10.1158/1078-0432.CCR-09-2933
119. Bartel D. P., MicroRNAs: target recognition and regulatory functions. Cell 2009 136 2 215 233
120. Lavon I., Zrihan D., Granit A., Einstein O., Fainstein N., Cohen M. A., Cohen M. A., Zelikovitch B., Shoshan Y., Spektor S., Reubinoff B. E., Felig Y., Gerlitz O., Ben-Hur T., Smith Y., Siegal T., Gliomas display a microRNA expression profile reminiscent of neural precursor cells. Neuro-Oncology 2010 12 5 422 433 2-s2.0-77954731887 10.1093/neuonc/nop061
121. van Jaarsveld M. T. M., Helleman J., Berns E. M. J. J., Wiemer E. A. C., MicroRNAs in ovarian cancer biology and therapy resistance. International Journal of Biochemistry and Cell Biology 2010 42 8 1282 1290 2-s2.0-77952671554 10.1016/j.biocel.2010.01.014
122. Xu C. X., Xu M., Tan L., MicroRNA MiR-214 regulates ovarian cancer cell stemness by targeting p53/Nanog. The Journal of Biological Chemistry 2012 287 42 34970 34978 10.1074/jbc.M112.374611
123. Cheng W., Liu T., Wan X., MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. The FEBS Journal 2012 279 11 2047 2059 10.1111/j.1742-4658.2012.08589.x
124. Wu Q., Guo R., Lin M., Zhou B., Wang Y., MicroRNA-200a inhibits CD133/1+ ovarian cancer stem cells migration and invasion by targeting E-cadherin repressor ZEB2. Gynecologic Oncology 2011 122 1 149 154 2-s2.0-79957741034 10.1016/j.ygyno.2011.03.026
125. Sarkar F. H., Li Y., Wang Z., Kong D., Ali S., Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resistance Updates 2010 13 3 57 66 2-s2.0-77953022034 10.1016/j.drup.2010.02.001
126. Zhong X., Li N., Liang S., Huang Q., Coukos G., Zhang L., Identification of microRNAs regulating reprogramming factor LIN28 in embryonic stem cells and cancer cells. Journal of Biological Chemistry 2010 285 53 41961 41971 2-s2.0-78650658030 10.1074/jbc.M110.169607
127. Fendler B., Atwal G., Systematic deciphering of cancer genome networks. Yale Journal of Biology and Medicine 2012 85 3 339 345
128. Williamson A. J., Whetton A. D., The requirement for proteomics to unravel stem cell regulatory mechanisms. Journal of Cellular Physiology 2011 226 10 2478 2483 2-s2.0-79960673730 10.1002/jcp.22610
129. Vathipadiekal V., Saxena D., Mok S. C., Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer. PLoS One 2012 7 1 1 12